The world's first malaria vaccine cleared one of the final hurdles as it received a positive scientific opinion from European regulators and now awaits approval from the WHO before it could be administered within the next few years across Africa. The vaccine, named Mosquirix, was Friday given the green light by London-based European Medicines Agency after more than 30 years of research, detailed in 230,000 pages of data. The vaccine will be examined by the WHO which will give its recommendation in November this year, and if approved, could be administered to children across Africa within the next few years.
A blog on current topics and exclusive articles.